Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

  • Torriani F
  • Rodriguez-Torres M
  • Rockstroh J
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • 0


    Citations of this article.


BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent and is associated with substantial morbidity and mortality among persons infected with the human immunodeficiency virus (HIV). We compared the efficacy and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of chronic HCV infection in patients who were also infected with HIV. METHODS: A total of 868 persons who were infected with both HIV and HCV and who had not previously been treated with interferon or ribavirin were randomly assigned to receive one of three regimens: peginterferon alfa-2a (180 microg per week) plus ribavirin (800 mg per day), peginterferon alfa-2a plus placebo, or interferon alfa-2a (3 million IU three times a week) plus ribavirin. Patients were treated for 48 weeks and followed for an additional 24 weeks. The primary end point was a sustained virologic response (defined as a serum HCV RNA level below 50 IU per milliliter at the end of follow-up, at week 72). RESULTS: The overall rate of sustained virologic response was significantly higher among the recipients of peginterferon alfa-2a plus ribavirin than among those assigned to interferon alfa-2a plus ribavirin (40 percent vs. 12 percent, P

Author-supplied keywords

  • Adult
  • Anemia
  • Antibodies
  • Antiviral Agents
  • Drug Therapy,Combination
  • Female
  • Genotype
  • HIV Infections
  • Hepacivirus
  • Hepatitis
  • Hepatitis C
  • Hepatitis C Antibodies
  • Hepatitis C,Chronic
  • Hiv
  • Human
  • Interferon Alfa-2a
  • Interferon Alfa-2b
  • Male
  • Morbidity
  • Research
  • Ribavirin
  • Rna
  • Rna,Viral
  • Safety
  • Support,Non-U.S.Gov't
  • Thrombocytopenia
  • adverse effects
  • blood
  • complications
  • drug effects
  • drug therapy
  • genetics
  • methods
  • mortality
  • therapeutic use

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • F J Torriani

  • M Rodriguez-Torres

  • J K Rockstroh

  • E Lissen

  • J Gonzalez-Garcia

  • A Lazzarin

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free